|Articles|May 8, 2018
The Missing Link in Amazon’s Healthcare Takeover
Author(s)Michelle Maskaly
John Cervione, managing partner of Blue Fin Group, talks briefly about Amazon’s foray into the healthcare and pharma industries.
Advertisement
John Cervione, managing partner of Blue Fin Group, talks briefly about Amazon’s foray into the healthcare and pharma industries, talks about what they are doing now, and the key element that is missing. His remarks come after a seminar at Asembia’s Specialty Pharmacy Summit in Las Vegas.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Lilly Reduces Price of Zepbound Single-Dose Vials for Self-Pay Patients
2
Pharmaceutical Commercialization: A 2026 Outlook Personalization and Precision Will Define a New Year in Pharma
3
FDA Announces Agency-Wide Deployment of Agentic AI Tools
4
Report: FDA to Change Vaccine Approval Process Based on Agency’s Claim of Covid Vaccine-Related Deaths
5
